REDUCED VOLUME CAPACITOR FOR IN VIVO DEFIBRILLATOR

用于体内除颤器的小容量电容器

• 批准号: 2229717
• 负责人: ANTON C GREENWALD
• 金额: $ 7.5万
• 依托单位: SPIRE CORPORATION
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-05-01 至 1994-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2229717
• 关键词: barium; biomedical equipment development; ceramics; dielectric property; implant; implantable defibrillators; molecular film; strontium; titanium; vapor

Over one-third the volume of in-the-body heart defibrillators is devoted to the capacitor, which consumes approximately 20 cm3; this volume could be reduced to less than 1 cm3 using proven integrated circuit technology. Employing metalorganic chemical vapor deposition (MOCVD), Spire proposes to form thin film ceramic capacitors having at least a hundred times greater energy density than is presently available from commercial products. MOCVD makes this possible by eliminating the voids and other field enhancing defects which limit capacitor performance. Spire's capacitors will be barium-strontium-titanate-based and will feature extremely high dielectric constant (over 1,000) and breakdown strength (100 V/micromoles). In Phase I, a single-layer 1 mu F, 1000 V capacitor will be fabricated and demonstrated as proof-of-principle that full-sized prototype capacitors can be built in Phase Il, where they would be made available to manufacturers of defibrillators for testing. Successful completion of the proposed program will lead to immediate introduction of smaller devices with improved patient comfort.

超过三分之一的体内心脏除颤器的体积 到电容器，它消耗大约20cm3；这个体积可以 使用经过验证的集成电路技术，可以减少到1立方米以下。 利用金属有机化学气相沉积(MOCVD)，斯皮尔提出 形成至少一百倍的薄膜陶瓷电容器 比目前商业广告提供的更高的能量密度 产品。MOCVD通过消除空洞和其他 限制电容器性能的场强缺陷。尖顶的 电容器将以钛酸锶钡为基础，并将具有 极高的介电常数(超过1,000)和击穿强度 (100V/微摩尔)。 在第一阶段，将制造单层1微伏、1000V的电容器，并 作为原理证明，全尺寸原型电容器 可以在Il阶段建造，在那里它们将可用于 用于测试的除颤器制造商。圆满完成 拟议的计划将导致立即推出更小的设备 改善了病人的舒适度。